Macquarie Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Macquarie Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,193	Closed	-$90K	–	2564
2022 Q2	$90K	Hold	1,193	–	–	﹤0.01%	1892
2022 Q1	$32	Sell	1,193 -25,958	-96%	-$872K	﹤0.01%	2284
2021 Q4	$1.29M	Buy	27,151 +4,727	+21%	+$211K	﹤0.01%	1502
2021 Q3	$1.49M	Hold	22,424	–	–	﹤0.01%	1475
2021 Q2	$1.75M	Buy	22,424 +5,356	+31%	+$396K	﹤0.01%	1450
2021 Q1	$1.61M	Buy	17,068 +2,344	+16%	+$279K	﹤0.01%	1265
2020 Q4	$1.79M	Buy	14,724 +1,572	+12%	+$172K	﹤0.01%	1139
2020 Q3	$1.15M	Buy	13,152 +11,989	+1,031%	+$835K	﹤0.01%	1207
2020 Q2	$75K	Buy	+1,163	New	+$67.1K	﹤0.01%	1833

Macquarie Group's TPTX Position: Q3 2022 in Review

Macquarie Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,193 shares — an estimated $90K sold.

Macquarie Group first reported a position in TPTX in Q2 2020 and held it in 9 quarters. The position peaked at $1.79M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Macquarie Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Macquarie Group sold 1,193 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $90K.
Macquarie Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
Macquarie Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.79M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.